BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38364651)

  • 21. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
    Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women.
    Sakurada S; Watanabe Y; Tokunaga H; Takahashi F; Yamada H; Takehara K; Yaegashi N
    Jpn J Clin Oncol; 2018 Sep; 48(9):794-798. PubMed ID: 29982601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
    Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
    J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
    Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ
    Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serous tubal in situ carcinoma (STIC) in primary peritoneal serous carcinomas.
    Horn LC; Kafkova S; Leonhardt K; Kellner C; Einenkel J
    Int J Gynecol Pathol; 2013 Jul; 32(4):339-44. PubMed ID: 23722505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.
    Bijron JG; van der Groep P; van Dorst EB; Seeber LM; Sie-Go DM; Verheijen RH; van Diest PJ
    Endocr Relat Cancer; 2012 Feb; 19(1):69-81. PubMed ID: 22143498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
    Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
    Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serous carcinogenesis in the fallopian tube: a descriptive classification.
    Jarboe E; Folkins A; Nucci MR; Kindelberger D; Drapkin R; Miron A; Lee Y; Crum CP
    Int J Gynecol Pathol; 2008 Jan; 27(1):1-9. PubMed ID: 18156967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
    Lee Y; Miron A; Drapkin R; Nucci MR; Medeiros F; Saleemuddin A; Garber J; Birch C; Mou H; Gordon RW; Cramer DW; McKeon FD; Crum CP
    J Pathol; 2007 Jan; 211(1):26-35. PubMed ID: 17117391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secretory cell outgrowths, p53 signatures, and serous tubal intraepithelial carcinoma in the fallopian tubes of patients with sporadic pelvic serous carcinoma.
    Mittal N; Srinivasan R; Gupta N; Rajwanshi A; Nijhawan R; Gautam U; Sood S; Dhaliwal L
    Indian J Pathol Microbiol; 2016; 59(4):481-488. PubMed ID: 27721278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma].
    Chêne G; Dauplat J; Radosevic-Robin N; Cayre A; Penault-Llorca F
    Bull Cancer; 2013; 100(7-8):757-64. PubMed ID: 23831931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls.
    Mehra KK; Chang MC; Folkins AK; Raho CJ; Lima JF; Yuan L; Mehrad M; Tworoger SS; Crum CP; Saleemuddin A
    Mod Pathol; 2011 Jan; 24(1):152-6. PubMed ID: 20871594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
    Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
    Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expansion of secretory cells in the fallopian tubal epithelium in the early stages of the pathogenesis of ovarian serous carcinomas].
    Asaturova AV; Ezhova LS; Faizullina NM; Adamyan LV; Khabas GN; Sannikova MV
    Arkh Patol; 2017; 79(3):10-18. PubMed ID: 28631711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.
    George SH; Milea A; Shaw PA
    Clin Cancer Res; 2012 Nov; 18(22):6199-207. PubMed ID: 22967960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
    Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
    Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
    Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
    Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.